PubMed · 12078438
[Novel compounds active on staphylococci].
Abstract
Research efforts to discover new compounds active against staphylococci are more than ever justified today. The incidence of methicillin-resistant staphylococci remains very high in hospitals, and the solution provided by glycopeptides is far from being satisfactory. These compounds exhibit mediocre pharmacokinetic and pharmacodynamic properties. Their ease and safety of use are poor. Finally, strains with diminished sensitivity to these antibiotics are beginning to appear. This article examines the opportunities offered by two new anti-staphylococcal agents: quinupristine-dalfopristine (Synercid) and linezolide (not marketed in France).
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
B Fantin. 2002. [Novel compounds active on staphylococci].. https://doi.org/10.1016/s0750-7658(02)00630-5
Cite the original work for its findings. Save a collection to share your selection of sources.